Compare RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) (RELX) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) vs Zoetis Inc — how do they compare? RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) trades at $36.73 (market cap $63.57B), while Zoetis Inc trades at $75.31 (market cap $30.70B). The key difference: RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) is far larger — about 2.1× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| RELX | ZTS | |
|---|---|---|
Market Cap | $63.57B | $30.70B |
Volume | 1,602,093 | 3,299,421 |
Sector | Industrials | Health |
52-Week High | $46.80 | $147.53 |
52-Week Low | $27.73 | $69.09 |
Enterprise Value | $75.05B | $38.27B |
Dividend Yield | 2.49% | 2.85% |
Typical Hold Time | — | 71 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RELX trades at $36.70, up 0.44% with neutral technical signals. The company demonstrates strong profitability with 23.27% net margins and 132.36% ROE, though valuation metrics appear elevated with P/E of 22.21 and P/B of 38.89. Recent earnings show mixed results with Q2 2026 beating expectations while Q4 2025 missed. Analyst sentiment remains positive with 71% buy ratings and consensus price target of $26.00.
The investment case balances strong fundamentals against premium valuation. Growth catalysts include AI-driven product adoption and margin expansion, while risks involve competitive pressures and valuation concerns. With solid cash flow generation and institutional support, RELX offers quality exposure but requires monitoring of valuation multiples and competitive dynamics.
Zoetis (ZTS) trades at $75.335, down 0.42% on the day, with a bullish technical signal from moving averages and ADX indicators. The company reported strong profitability with a 27.69% net income margin and 64.91% ROE for 2025, though Q1 2026 EPS missed expectations. Recent news highlights near-term headwinds in U.S. companion animal sales but underscores long-term resilience and industry-leading margins.
The outlook is cautiously optimistic, with a consensus price target of $87.33 implying 16% upside. Investment opportunities lie in Zoetis's robust fundamentals and market dominance, while risks include competitive pressures, weaker U.S. demand, and margin compression from promotions. The stock offers value at a P/E of 12.12, but investors should monitor Q3 2026 results for growth confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share)
RELX PLC is a UK-based information and analytics company operating across four segments: Risk (fraud prevention and compliance analytics via LexisNexis Risk Solutions), Scientific, Technical & Medical (Elsevier's research and clinical content), Legal (LexisNexis Legal & Professional's research tools), and Exhibitions (RX's trade events). It serves professional, business, and government customers worldwide.
Read more on RELX →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
